Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting.
暂无分享,去创建一个
A. Hauschild | D. Schadendorf | W. Stolz | U. Reinhold | R. Dummer | A. Mackensen | C. Garbe | M. Volkenandt | G. Schuler | R. Kortmann | B. Frerich | R. Kaufmann | W. Tilgen | C. Kettelhack | U. Keilholz | G. Sebastian
[1] Franco Patrone,et al. The use of dendritic cells in cancer immunotherapy. , 2008, Critical reviews in oncology/hematology.
[2] A. Hauschild,et al. Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma. , 2007, Melanoma research.
[3] R. Stupp,et al. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] A. Eggermont,et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial , 2005, The Lancet.
[5] D. Schadendorf,et al. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. , 2004, European journal of cancer.
[6] C. Jacquillat,et al. Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma , 2004, Cancer Chemotherapy and Pharmacology.
[7] G. Westbury,et al. Vindesine as a single agent in the treatment of advanced malignant melanoma , 2004, Cancer Chemotherapy and Pharmacology.
[8] M. Weichenthal,et al. Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] S. Ugurel,et al. Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study , 2003, Anti-cancer drugs.
[10] A. Mackensen,et al. Survival and Tumor Localization of Adoptively Transferred Melan-A-Specific T Cells in Melanoma Patients 1 , 2003, The Journal of Immunology.
[11] A. Hauschild,et al. A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma , 2003, Melanoma research.
[12] M. Raffeld,et al. Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.
[13] M. Gore,et al. Interferon as adjuvant treatment for melanoma , 2002, The Lancet.
[14] R. Bukowski,et al. Treating cancer with PEG Intron , 2002, Cancer.
[15] G. Schuler,et al. Rapid Induction of Tumor-specific Type 1 T Helper Cells in Metastatic Melanoma Patients by Vaccination with Mature, Cryopreserved, Peptide-loaded Monocyte-derived Dendritic Cells , 2002, The Journal of experimental medicine.
[16] J. Lee,et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] O. Nanni,et al. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] E. Bröcker,et al. Combination chemotherapy with or without s.c. IL-2 and IFN-α: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM) , 2002, British Journal of Cancer.
[19] J. Dunn,et al. Prospective Randomized Comparison of Dacarbazine (DTIC) Versus DTIC Plus Interferon-Alpha (IFN-α) in Metastatic Melanoma , 2001 .
[20] Dan Ferber,et al. Safer and Virus-Free? , 2001, Science.
[21] N. Cascinelli,et al. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial , 2001, The Lancet.
[22] K. Horgan,et al. MRI enables accurate diagnosis and single stage surgical resection of invasive lobular breast cancers , 2001 .
[23] R. Steinman,et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. , 2001, Cancer research.
[24] V. Sondak,et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] M. Gore,et al. Adjuvant interferon alpha 2b in high risk melanoma – the Scottish study , 2001, British Journal of Cancer.
[26] A. Hauschild,et al. Histamine dihydrochloride administered with interleukin-2 increases survival duration in patients with ocular melanoma with liver metastases , 2001 .
[27] A. Paccagnella,et al. Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients , 2001, Melanoma research.
[28] T. Lehnert,et al. Pilot study of hepatic intraarterial fotemustine chemotherapy for liver metastases from uveal melanoma: a single-center experience with seven patients , 2001, International Journal of Clinical Oncology.
[29] D. Schadendorf,et al. Autologous dendritic cells for treatment of advanced cancer--an update. , 2001, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[30] J. Dunn,et al. Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma. , 2001, Clinical oncology (Royal College of Radiologists (Great Britain)).
[31] D. Ferber. Gene therapy. Safer and virus-free? , 2001, Science.
[32] A. Hauschild,et al. [Adjuvant drug therapy of malignant melanoma. Current knowledge and multi-center studies in German-speaking countries]. , 2000, Deutsche medizinische Wochenschrift.
[33] V. Sondak,et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] S. Soong,et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] D. Schadendorf,et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] A. Enk,et al. Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma , 1999, The Journal of experimental medicine.
[37] S. Groshen,et al. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[38] C. Begg,et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] E. Celis,et al. A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma. , 1999, Journal of immunotherapy.
[40] R. Fisher,et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] K. Rowland,et al. Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] M. Avril,et al. Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study. , 1999, Cancer.
[43] P. Coulie,et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1 , 1999, International journal of cancer.
[44] A. Hauschild,et al. Combined interferon-α and interleukin-2 as adjuvant treatment for melanoma , 1998, The Lancet.
[45] A. Eggermont,et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, a , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] S. Aamdal,et al. Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trial. , 1998, European journal of cancer.
[47] C. Chastang,et al. Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1·5 mm without clinically detectable node metastases , 1998, The Lancet.
[48] M. Atkins,et al. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] F. Marincola,et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.
[50] M. Binder,et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] Dirk Schadendorf,et al. Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.
[52] A. Hauschild,et al. Combined interferon-alpha and interleukin-2 as adjuvant treatment for melanoma. , 1998, Lancet.
[53] C. Chastang,et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. , 1998, Lancet.
[54] N. Barth,et al. Long-term survival after continuous infusion interleukin-2. , 1997, Cancer biotherapy & radiopharmaceuticals.
[55] A. Enk,et al. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] R. Meuli,et al. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] F. Marincola,et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. , 1997, The cancer journal from Scientific American.
[58] J. Kirkwood,et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] S. Legha,et al. Evaluation of interleukin‐2 administered by continuous infusion in patients with metastatic melanoma , 1996, Cancer.
[60] N. Bleehen,et al. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] K. Bland,et al. A phase III randomized, doúble‐blind, multiinstitutional trial of vaccinia melanoma oncolysate‐active specific immunotherapy for patients with stage II melanoma , 1995, Cancer.
[62] K. Henry,et al. Clinical and histologic involvement of regional lymph nodes in malignant melanoma. Adjuvant vindesine improves survival. , 1995, Cancer.
[63] V. Sondak,et al. Randomized trial of vitamin A versus observation as adjuvant therapy in high-risk primary malignant melanoma: a Southwest Oncology Group study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] G. Wong,et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] N. Cascinelli,et al. Results of adjuvant interferon study In WHO melanoma programme , 1994, The Lancet.
[66] P. Queirolo,et al. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] D. Pectasides,et al. Adjuvant Chemotherapy With Dacarbazine, Vindesine, and Cisplatin in Pathological Stage II Malignant Melanoma , 1994, American journal of clinical oncology.
[68] C. Garbe,et al. [Adjuvant therapy of primary malignant melanoma with natural human interferon-beta. Significant survival advantage in 96 treated patients in comparison with 288 untreated symptomatic controls]. , 1993, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.
[69] P. Steerenberg,et al. Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment in a randomised multicentre study (EORTC Protocol 18781). , 1993, European journal of cancer.
[70] L. Blumenson,et al. Adjuvant chemotherapy with a nitrosourea-based protocol in advanced malignant melanoma. , 1993, European journal of cancer.
[71] V. Doherty,et al. Nine years’ experience of BELD combination chemotherapy (bleomycin, vindesine, CCNU and DTIC) for metastatic melanoma , 1992, The British journal of dermatology.
[72] D. Khayat,et al. Fotemustine: an overview of its clinical activity in disseminated malignant melanoma. , 1992, Melanoma research.
[73] K. Smith,et al. Interferon alpha2a and vindesine in the treatment of advanced malignant melanoma , 1992 .
[74] K. Smith,et al. Interferon alpha 2a and vindesine in the treatment of advanced malignant melanoma. , 1992, European journal of cancer.
[75] D. Reintgen,et al. Adjuvant chemotherapy in malignant melanoma using dacarbazine, carmustine, cisplatin, and tamoxifen: a University of South Florida and H. Lee Moffitt Melanoma Center Study. , 1992, Annals of plastic surgery.
[76] C. Coltman,et al. Recombinant human interferon gamma: adverse effects in high-risk stage I and II cutaneous malignant melanoma. , 1990, Journal of the National Cancer Institute.
[77] G. Hortobagyi,et al. Adjuvant systemic therapy , 1990, Cancer.
[78] C. Garbe,et al. [Chemotherapy of malignant melanoma--current status]. , 1990, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.
[79] D. Pectasides,et al. Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin. , 1989, British Journal of Cancer.
[80] D. Longo,et al. Randomized trial of recombinant alpha 2b-interferon with or without indomethacin in patients with metastatic malignant melanoma. , 1989, Cancer research.
[81] D. Schaid,et al. A Prospective, Randomized Controlled Trial of Megestrol Acetate Among High‐Risk Patients with Resected Malignant Melanoma , 1989, American journal of clinical oncology.
[82] H. Strander,et al. Dacarbazine versus dacarbazine-vindesine in disseminated malignant melanoma: A randomized phase II study , 1989, Medical oncology and tumor pharmacotherapy.
[83] S. Rosenberg,et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.
[84] J. Mulder,et al. Combination of cisplatin, vindesine, and dacarbazine in advanced malignant melanoma. A phase II study of the eortc malignant melanoma cooperative group , 1988, Cancer.
[85] A. Foltz,et al. Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma , 1988, Cancer.
[86] D. Minor,et al. A randomized, double‐blind, placebo‐controlled trial of transfer factor as adjuvant therapy for malignant melanoma , 1988, Cancer.
[87] S. Balcerzak,et al. Lack of benefit of adjunctive chemotherapy in stage I malignant melanoma: a Southwest Oncology Group Study. , 1987, Cancer treatment reports.
[88] M. Mastrangelo,et al. Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. , 1987, Cancer treatment reports.
[89] R. Spiegel,et al. Treatment of metastatic malignant melanoma with recombinant interferon alpha 2. , 1986, Immunobiology.
[90] C. Presant,et al. Ineffectiveness of adjuvant chemotherapy using DTIC and cyclophosphamide in patients with resectable metastatic melanoma. , 1984, Surgery.
[91] B. Peterson,et al. Vindesine for metastatic malignant melanoma. A phase II trial. , 1983, American Journal of Clinical Oncology.
[92] K. Calman,et al. A multicentre phase II trial of vindesine in malignant melanoma. , 1982, European journal of cancer & clinical oncology.
[93] N. Cascinelli,et al. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. , 1982, The New England journal of medicine.
[94] C. Fabian,et al. Combination chemotherapy plus BCG in the treatment of disseminated malignant melanoma: a Southwest Oncology Group Study. , 1982, Medical and pediatric oncology.
[95] H. Bingham,et al. DTIC and combination therapy for melanoma , 1981 .
[96] S. Moss,et al. DTIC and combination therapy for melanoma: III. DTIC (NSC 45388) surgical adjuvant study COG PROTOCOL 7040 , 1981, Cancer.
[97] R. Sagebiel,et al. A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. , 1991, The New England journal of medicine.
[98] A. Huang,et al. DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma , 1980, Cancer.
[99] E. Krementz,et al. DTIC (nsc-45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065). , 1976, Cancer treatment reports.
[100] J. Van Dyk,et al. A clinical trial of procarbazine plus vincristine plus bis-chloroethyl-nitrosourea plus imidazole carboxamide dimethyl triazeno in metastatic malignant melanoma. , 1975, Medical and pediatric oncology.